{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:17:53Z","timestamp":1788322673753,"version":"build-2803163510"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11684-021-0901-2","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T13:19:13Z","timestamp":1654867153000},"page":"322-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success?"],"prefix":"10.1007","volume":"16","author":[{"given":"Pooria","family":"Safarzadeh Kozani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"7","key":"901_CR1","doi-asserted-by":"publisher","first-page":"101079","DOI":"10.1016\/j.tranon.2021.101079","volume":"14","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: new roads; old destination. Transl Oncol 2021; 14(7): 101079","journal-title":"Transl Oncol"},{"issue":"11","key":"901_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12032-020-01416-3","volume":"37","author":"M Hashem Boroojerdi","year":"2020","unstructured":"Hashem Boroojerdi M, Rahbarizadeh F, Safarzadeh Kozani P, Kamali E, Safarzadeh Kozani P. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Med Oncol 2020; 37(11): 100","journal-title":"Med Oncol"},{"issue":"10","key":"901_CR3","first-page":"669","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov 2017; 16(10): 669","journal-title":"Nat Rev Drug Discov"},{"key":"901_CR4","doi-asserted-by":"crossref","unstructured":"No author listed. FDA approves second CAR T-cell therapy. Cancer Discov 2018; 8(1): 5\u20136","DOI":"10.1158\/2159-8290.CD-NB2017-155"},{"issue":"9","key":"901_CR5","first-page":"832","volume":"324","author":"R Voelker","year":"2020","unstructured":"Voelker R. CAR-T therapy is approved for mantle cell lymphoma. JAMA 2020; 324(9): 832","journal-title":"JAMA"},{"issue":"5","key":"901_CR6","first-page":"332","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 2021; 20(5): 332","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"901_CR7","first-page":"166","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approves fourth CAR-T cell therapy. Nat Rev Drug Discov 2021; 20(3): 166","journal-title":"Nat Rev Drug Discov"},{"issue":"924","key":"901_CR8","doi-asserted-by":"publisher","first-page":"627549","DOI":"10.3389\/fonc.2021.627549","volume":"11","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F, Khoshtinat Nikkhoi S. Strategies for dodging the obstacles in CAR T cell therapy. Front Oncol 2021; 11(924): 627549","journal-title":"Front Oncol"},{"issue":"6","key":"901_CR9","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol 2019; 16(6): 372\u2013385","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"901_CR10","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1158\/1535-7163.MCT-20-1089","volume":"20","author":"P Safarzadeh Kozani","year":"2021","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, O\u2019Connor RS. In like a lamb; out like a lion: marching CAR-T cells towards enhanced efficacy in B-ALL. Mol Cancer Ther 2021; 20(7): 1223\u20131233","journal-title":"Mol Cancer Ther"},{"issue":"6382","key":"901_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science 2018; 359(6382): 1361\u20131365","journal-title":"Science"},{"issue":"4","key":"901_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/2326-6066.CIR-20-0451","volume":"9","author":"E Landoni","year":"2021","unstructured":"Landoni E, Fuc\u00e1 G, Wang J, Chirasani VR, Yao Z, Dukhovlinova E, Ferrone S, Savoldo B, Hong LK, Shou P, Musio S, Padelli F, Finocchiaro G, Droste M, Kuhlman B, Shamshiev A, Pellegatta S, Dokholyan NV, Dotti G. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling. Cancer Immunol Res 2021; 9(4): 441\u2013453","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"901_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21(6): 581\u2013590","journal-title":"Nat Med"},{"issue":"9","key":"901_CR14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther 2018; 17(9): 1795\u20131815","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"901_CR15","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41591-021-01340-7","volume":"27","author":"K Hege","year":"2021","unstructured":"Hege K. Context matters in CAR T cell tonic signaling. Nat Med 2021; 27(5): 763\u2013764","journal-title":"Nat Med"},{"issue":"1","key":"901_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms12010001","volume":"12","author":"JX Zhao","year":"2010","unstructured":"Zhao JX, Yang L, Gu ZN, Chen HQ, Tian FW, Chen YQ, Zhang H, Chen W. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity. Int J Mol Sci 2010; 12(1): 1\u201311","journal-title":"Int J Mol Sci"},{"key":"901_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","volume":"141","author":"F Rahbarizadeh","year":"2019","unstructured":"Rahbarizadeh F, Ahmadvand D, Moghimi SM. CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev 2019; 141: 41\u201346","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"901_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2012.08.010","volume":"334","author":"Z Sharifzadeh","year":"2013","unstructured":"Sharifzadeh Z, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Jamnani FR, Moghimi SM. Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. Cancer Lett 2013; 334(2): 237\u2013244","journal-title":"Cancer Lett"},{"issue":"1","key":"901_CR19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbagen.2013.09.029","volume":"1840","author":"FR Jamnani","year":"2014","unstructured":"Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L, Moghimi SM. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy. Biochim Biophys Acta 2014; 1840(1): 378\u2013386","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"901_CR20","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s12185-012-1037-6","volume":"95","author":"S Khaleghi","year":"2012","unstructured":"Khaleghi S, Rahbarizadeh F, Ahmadvand D, Rasaee MJ, Pognonec P. A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol 2012; 95(4): 434\u2013444","journal-title":"Int J Hematol"},{"issue":"4","key":"901_CR21","first-page":"502","volume":"22","author":"A Rajabzadeh","year":"2021","unstructured":"Rajabzadeh A, Rahbarizadeh F, Ahmadvand D, Kabir Salmani M, Hamidieh AA. A VHH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells. Cell J 2021; 22(4): 502\u2013513","journal-title":"Cell J"},{"issue":"18","key":"901_CR22","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/j.yexcr.2011.08.015","volume":"317","author":"FJ Iri-Sofla","year":"2011","unstructured":"Iri-Sofla FJ, Rahbarizadeh F, Ahmadvand D, Rasaee MJ. Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by \u03c6C31 integrase. Exp Cell Res 2011; 317(18): 2630\u20132641","journal-title":"Exp Cell Res"},{"issue":"2","key":"901_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/hyb.2008.0079","volume":"28","author":"SH Bakhtiari","year":"2009","unstructured":"Bakhtiari SH, Rahbarizadeh F, Hasannia S, Ahmadvand D, Iri-Sofla FJ, Rasaee MJ. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma (Larchmt) 2009; 28(2): 85\u201392","journal-title":"Hybridoma (Larchmt)"},{"issue":"3","key":"901_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021; 21(3): 145\u2013161","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"901_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 2020; 17(3): 147\u2013167","journal-title":"Nat Rev Clin Oncol"},{"issue":"7283","key":"901_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nature08746","volume":"463","author":"JB Huppa","year":"2010","unstructured":"Huppa JB, Axmann M, M\u00f6rtelmaier MA, Lillemeier BF, Newell EW, Brameshuber M, Klein LO, Sch\u00fctz GJ, Davis MM. TCR-peptide-MHC interactions in situ show accelerated kinetics and increased affinity. Nature 2010; 463(7283): 963\u2013967","journal-title":"Nature"},{"issue":"5","key":"901_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.immuni.2013.08.036","volume":"39","author":"J Huang","year":"2013","unstructured":"Huang J, Brameshuber M, Zeng X, Xie J, Li QJ, Chien YH, Valitutti S, Davis MM. A single peptide-major histocompatibility complex ligand triggers digital cytokine secretion in CD4+ T cells. Immunity 2013; 39(5): 846\u2013857","journal-title":"Immunity"},{"issue":"1","key":"901_CR28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.immuni.2007.05.017","volume":"27","author":"M Huse","year":"2007","unstructured":"Huse M, Klein LO, Girvin AT, Faraj JM, Li QJ, Kuhns MS, Davis MM. Spatial and temporal dynamics of T cell receptor signaling with a photoactivatable agonist. Immunity 2007; 27(1): 76\u201388","journal-title":"Immunity"},{"issue":"17","key":"901_CR29","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","volume":"25","author":"S Ramakrishna","year":"2019","unstructured":"Ramakrishna S, Highfill SL, Walsh Z, Nguyen SM, Lei H, Shern JF, Qin H, Kraft IL, Stetler-Stevenson M, Yuan CM, Hwang JD, Feng Y, Zhu Z, Dimitrov D, Shah NN, Fry TJ. Modulation of target antigen density improves CAR T-cell functionality and persistence. Clin Cancer Res 2019; 25(17): 5329\u20135341","journal-title":"Clin Cancer Res"},{"issue":"5","key":"901_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, Myklebust JH, Kadapakkam M, Weber EW, Tousley AM, Richards RM, Heitzeneder S, Nguyen SM, Wiebking V, Theruvath J, Lynn RC, Xu P, Dunn AR, Vale RD, Mackall CL. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov 2020; 10(5): 702\u2013723","journal-title":"Cancer Discov"},{"issue":"4","key":"901_CR31","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","volume":"108","author":"E Donnadieu","year":"2020","unstructured":"Donnadieu E, Dupr\u00e9 L, Pinho LG, Cotta-de-Almeida V. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. J Leukoc Biol 2020; 108(4): 1067\u20131079","journal-title":"J Leukoc Biol"},{"issue":"7","key":"901_CR32","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1134\/S0006297915070019","volume":"80","author":"U Karsten","year":"2015","unstructured":"Karsten U, Goletz S. What controls the expression of the core-1 (Thomsen-Friedenreich) glycotope on tumor cells? Biochemistry (Mosc) 2015; 80(7): 801\u2013807","journal-title":"Biochemistry (Mosc)"},{"issue":"12","key":"901_CR33","first-page":"4851","volume":"61","author":"VV Glinsky","year":"2001","unstructured":"Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001; 61(12): 4851\u20134857","journal-title":"Cancer Res"},{"issue":"9","key":"901_CR34","doi-asserted-by":"publisher","first-page":"e25007","DOI":"10.1371\/journal.pone.0025007","volume":"6","author":"CF Bian","year":"2011","unstructured":"Bian CF, Zhang Y, Sun H, Li DF, Wang DC. Structural basis for distinct binding properties of the human galectins to Thomsen-Friedenreich antigen. PLoS One 2011; 6(9): e25007","journal-title":"PLoS One"},{"issue":"4","key":"901_CR35","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s10875-012-9653-8","volume":"32","author":"HD Chen","year":"2012","unstructured":"Chen HD, Zhou X, Yu G, Zhao YL, Ren Y, Zhou YD, Li Q, Zhang XL. Knockdown of core 1 beta 1, 3-galactosyltransferase prolongs skin allograft survival with induction of galectin-1 secretion and suppression of CD8+ T cells: T synthase knockdown effects on galectin-1 and CD8+ T cells. J Clin Immunol 2012; 32(4): 820\u2013836","journal-title":"J Clin Immunol"},{"issue":"6","key":"901_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/tan.12900","volume":"88","author":"C Fu","year":"2016","unstructured":"Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y, Chen H. Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA 2016; 88(6): 275\u2013286","journal-title":"HLA"},{"issue":"17","key":"901_CR37","first-page":"4741","volume":"52","author":"S Ogata","year":"1992","unstructured":"Ogata S, Maimonis PJ, Itzkowitz SH. Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity. Cancer Res 1992; 52(17): 4741\u20134746","journal-title":"Cancer Res"},{"issue":"7\u20139","key":"901_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1023\/B:GLYC.0000014084.01324.15","volume":"19","author":"Y Takenaka","year":"2002","unstructured":"Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J 2002; 19(7\u20139): 543\u2013549","journal-title":"Glycoconj J"},{"issue":"5","key":"901_CR39","doi-asserted-by":"publisher","first-page":"e0125994","DOI":"10.1371\/journal.pone.0125994","volume":"10","author":"R Beatson","year":"2015","unstructured":"Beatson R, Maurstad G, Picco G, Arulappu A, Coleman J, Wandell HH, Clausen H, Mandel U, Taylor-Papadimitriou J, Sletmoen M, Burchell JM. The breast cancer-associated glycoforms of MUC1, MUC1-Tn and sialyl-Tn, are expressed in COSMC wild-type cells and bind the C-Type lectin MGL. PLoS One 2015; 10(5): e0125994","journal-title":"PLoS One"},{"issue":"2","key":"901_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","volume":"249","author":"S Pinho","year":"2007","unstructured":"Pinho S, Marcos NT, Ferreira B, Carvalho AS, Oliveira MJ, Santos-Silva F, Harduin-Lepers A, Reis CA. Biological significance of cancer-associated sialyl-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 2007; 249(2): 157\u2013170","journal-title":"Cancer Lett"},{"issue":"2","key":"901_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.imbio.2014.10.002","volume":"220","author":"Y van Kooyk","year":"2015","unstructured":"van Kooyk Y, Ilarregui JM, van Vliet SJ. Novel insights into the immunomodulatory role of the dendritic cell and macrophage-expressed C-type lectin MGL. Immunobiology 2015; 220(2): 185\u2013192","journal-title":"Immunobiology"},{"issue":"38","key":"901_CR42","doi-asserted-by":"publisher","first-page":"27519","DOI":"10.1074\/jbc.M113.471045","volume":"288","author":"SJ van Vliet","year":"2013","unstructured":"van Vliet SJ, Vuist IM, Lenos K, Tefsen B, Kalay H, Garc\u00eda-Vallejo JJ, van Kooyk Y. Human T cell activation results in extracellular signal-regulated kinase (ERK)-calcineurin-dependent exposure of Tn antigen on the cell surface and binding of the macrophage galactose-type lectin (MGL). J Biol Chem 2013; 288(38): 27519\u201327532","journal-title":"J Biol Chem"},{"issue":"3","key":"901_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/1097-0142(19850201)55:3<561::AID-CNCR2820550315>3.0.CO;2-1","volume":"55","author":"GF Springer","year":"1985","unstructured":"Springer GF, Taylor CR, Howard DR, Tegtmeyer H, Desai PR, Murthy SM, Felder B, Scanlon EF. Tn, a carcinoma-associated antigen, reacts with anti-Tn of normal human sera. Cancer 1985; 55(3): 561\u2013569","journal-title":"Cancer"},{"issue":"8","key":"901_CR44","first-page":"2214","volume":"48","author":"T Kjeldsen","year":"1988","unstructured":"Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2\u20136 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988; 48(8): 2214\u20132220","journal-title":"Cancer Res"},{"issue":"6","key":"901_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/0016-5085(91)90671-7","volume":"100","author":"S Itzkowitz","year":"1991","unstructured":"Itzkowitz S, Kjeldsen T, Friera A, Hakomori S, Yang US, Kim YS. Expression of Tn, sialosyl Tn, and T antigens in human pancreas. Gastroenterology 1991; 100(6): 1691\u20131700","journal-title":"Gastroenterology"},{"issue":"1","key":"901_CR46","first-page":"197","volume":"49","author":"SH Itzkowitz","year":"1989","unstructured":"Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989; 49(1): 197\u2013204","journal-title":"Cancer Res"},{"issue":"2","key":"901_CR47","first-page":"305","volume":"15","author":"G Konska","year":"2006","unstructured":"Konska G, Guerry M, Caldefie-Chezet F, De Latour M, Guillot J. Study of the expression of Tn antigen in different types of human breast cancer cells using VVA-B4 lectin. Oncol Rep 2006; 15(2): 305\u2013310","journal-title":"Oncol Rep"},{"issue":"6","key":"901_CR48","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.1991.9.6.983","volume":"9","author":"H Kobayashi","year":"1991","unstructured":"Kobayashi H, Terao T, Kawashima Y. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. J Clin Oncol 1991; 9(6): 983\u2013987","journal-title":"J Clin Oncol"},{"issue":"4","key":"901_CR49","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/IGC.0b013e3182473292","volume":"22","author":"K Akita","year":"2012","unstructured":"Akita K, Yoshida S, Ikehara Y, Shirakawa S, Toda M, Inoue M, Kitawaki J, Nakanishi H, Narimatsu H, Nakada H. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int J Gynecol Cancer 2012; 22(4): 531\u2013538","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"901_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/CBM-130375","volume":"14","author":"T Ju","year":"2014","unstructured":"Ju T, Aryal RP, Kudelka MR, Wang Y, Cummings RD. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark 2014; 14(1): 63\u201381","journal-title":"Cancer Biomark"},{"issue":"1","key":"901_CR51","doi-asserted-by":"publisher","first-page":"6937","DOI":"10.1038\/ncomms7937","volume":"6","author":"E Lira-Navarrete","year":"2015","unstructured":"Lira-Navarrete E, de Las Rivas M, Compa\u00f1\u00f3n I, Pallar\u00e9s MC, Kong Y, Iglesias-Fern\u00e1ndez J, Bernardes GJ, Peregrina JM, Rovira C, Bernad\u00f3 P, Bruscolini P, Clausen H, Lostao A, Corzana F, Hurtado-Guerrero R. Dynamic interplay between catalytic and lectin domains of GalNAc-transferases modulates protein O-glycosylation. Nat Commun 2015; 6(1): 6937","journal-title":"Nat Commun"},{"issue":"1","key":"901_CR52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10120-014-0454-z","volume":"19","author":"F Tamura","year":"2016","unstructured":"Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T, Okagawa Y, Uemura N, Arihara Y, Murase K, Kawano Y, Iyama S, Takada K, Hayashi T, Sato T, Miyanishi K, Kobune M, Takimoto R, Kato J. RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer 2016; 19(1): 85\u201397","journal-title":"Gastric Cancer"},{"issue":"6","key":"901_CR53","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","volume":"68","author":"T Ju","year":"2008","unstructured":"Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res 2008; 68(6): 1636\u20131646","journal-title":"Cancer Res"},{"issue":"12","key":"901_CR54","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1093\/ndt\/gfq325","volume":"25","author":"K Yamada","year":"2010","unstructured":"Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN, Tomino Y. Down-regulation of core 1 \u03b21,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 2010; 25(12): 3890\u20133897","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"901_CR55","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1172\/JCI116434","volume":"91","author":"M Thurnher","year":"1993","unstructured":"Thurnher M, Rusconi S, Berger EG. Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome. J Clin Invest 1993; 91(5): 2103\u20132110","journal-title":"J Clin Invest"},{"issue":"5","key":"901_CR56","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1083\/jcb.201003055","volume":"189","author":"DJ Gill","year":"2010","unstructured":"Gill DJ, Chia J, Senewiratne J, Bard F. Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol 2010; 189(5): 843\u2013858","journal-title":"J Cell Biol"},{"issue":"1","key":"901_CR57","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jcp.21744","volume":"220","author":"A Rivinoja","year":"2009","unstructured":"Rivinoja A, Hassinen A, Kokkonen N, Kauppila A, Kellokumpu S. Elevated Golgi pH impairs terminal N-glycosylation by inducing mislocalization of Golgi glycosyltransferases. J Cell Physiol 2009; 220(1): 144\u2013154","journal-title":"J Cell Physiol"},{"issue":"1","key":"901_CR58","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/glycob\/cwj033","volume":"16","author":"S Julien","year":"2006","unstructured":"Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter-Edouart AS, Hanisch FG, Delannoy P, Le Bourhis X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006; 16(1): 54\u201364","journal-title":"Glycobiology"},{"issue":"10","key":"901_CR59","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/glycob\/cwi085","volume":"15","author":"R Kabu\u00df","year":"2005","unstructured":"Kabu\u00df R, Ashikov A, Oelmann S, Gerardy-Schahn R, Bakker H. Endoplasmic reticulum retention of the large splice variant of the UDP-galactose transporter is caused by a dilysine motif. Glycobiology 2005; 15(10): 905\u2013911","journal-title":"Glycobiology"},{"issue":"23","key":"901_CR60","doi-asserted-by":"publisher","first-page":"17771","DOI":"10.1074\/jbc.M110.103184","volume":"285","author":"A Hassinen","year":"2010","unstructured":"Hassinen A, Rivinoja A, Kauppila A, Kellokumpu S. Golgi N-glycosyltransferases form both homo- and heterodimeric enzyme complexes in live cells. J Biol Chem 2010; 285(23): 17771\u201317777","journal-title":"J Biol Chem"},{"issue":"4","key":"901_CR61","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/glycob\/cwz004","volume":"29","author":"C Steentoft","year":"2019","unstructured":"Steentoft C, Fuhrmann M, Battisti F, Van Coillie J, Madsen TD, Campos D, Halim A, Vakhrushev SY, Joshi HJ, Schreiber H, Mandel U, Narimatsu Y. A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: identification of a novel dysadherin-Tn antibody. Glycobiology 2019; 29(4): 307\u2013319","journal-title":"Glycobiology"},{"issue":"1","key":"901_CR62","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1073\/pnas.012425299","volume":"99","author":"Y Ino","year":"2002","unstructured":"Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis. Proc Natl Acad Sci USA 2002; 99(1): 365\u2013370","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"901_CR63","first-page":"231","volume":"29","author":"X Huang","year":"2012","unstructured":"Huang X, Wang B, Yang D, Shi X, Hong J, Wang S, Dai X, Zhou X, Geng YJ. Reduced expression of FXYD domain containing ion transport regulator 5 in association with hypertension. Int J Mol Med 2012; 29(2): 231\u2013238","journal-title":"Int J Mol Med"},{"issue":"11","key":"901_CR64","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother 2017; 66(11): 1425\u20131436","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"901_CR65","doi-asserted-by":"publisher","first-page":"e21146","DOI":"10.1371\/journal.pone.0021146","volume":"6","author":"C Zheng","year":"2011","unstructured":"Zheng C, Feng J, Lu D, Wang P, Xing S, Coll JL, Yang D, Yan X. A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity. PLoS One 2011; 6(6): e21146","journal-title":"PLoS One"},{"issue":"13","key":"901_CR66","first-page":"3419","volume":"60","author":"C Ordo\u00f1ez","year":"2000","unstructured":"Ordo\u00f1ez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 2000; 60(13): 3419\u20133424","journal-title":"Cancer Res"},{"issue":"1","key":"901_CR67","doi-asserted-by":"publisher","first-page":"24823","DOI":"10.1038\/srep24823","volume":"6","author":"Y Sato","year":"2016","unstructured":"Sato Y, Tateno H, Adachi J, Okuyama H, Endo H, Tomonaga T, Inoue M. Generation of a monoclonal antibody recognizing the CEACAM glycan structure and inhibiting adhesion using cancer tissue-originated spheroid as an antigen. Sci Rep 2016; 6(1): 24823","journal-title":"Sci Rep"},{"key":"901_CR68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/B978-0-12-381462-3.00022-7","volume-title":"Seldin and Giebisch\u2019s The Kidney","author":"Y Maezawa","year":"2013","unstructured":"Maezawa Y, Cina D, Quaggin SE. Glomerular cell biology. In: Alpern RJ, Moe OW, Caplan M. Seldin and Giebisch\u2019s The Kidney. 5th ed. Cambridge, USA: Academic Press, 2013. 721\u2013755","edition":"5th ed."},{"issue":"2","key":"901_CR69","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3892\/ijo.2014.2427","volume":"45","author":"CW Lin","year":"2014","unstructured":"Lin CW, Sun MS, Wu HC. Podocalyxin-like 1 is associated with tumor aggressiveness and metastatic gene expression in human oral squamous cell carcinoma. Int J Oncol 2014; 45(2): 710\u2013718","journal-title":"Int J Oncol"},{"issue":"2","key":"901_CR70","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.bbrc.2008.07.049","volume":"374","author":"N Hayatsu","year":"2008","unstructured":"Hayatsu N, Kaneko MK, Mishima K, Nishikawa R, Matsutani M, Price JE, Kato Y. Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun 2008; 374(2): 394\u2013398","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"901_CR71","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bjc.2011.295","volume":"105","author":"A Larsson","year":"2011","unstructured":"Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhl\u00e9n M, Jirstr\u00f6m K. Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 2011; 105(5): 666\u2013672","journal-title":"Br J Cancer"},{"issue":"7","key":"901_CR72","doi-asserted-by":"publisher","first-page":"e0131605","DOI":"10.1371\/journal.pone.0131605","volume":"10","author":"TN Flores-T\u00e9llez","year":"2015","unstructured":"Flores-T\u00e9llez TN, Lopez TV, V\u00e1squez Garz\u00f3n VR, Villa-Trevi\u00f1o S. Co-expression of Ezrin-CLIC5-podocalyxin is associated with migration and invasiveness in hepatocellular carcinoma. PLoS One 2015; 10(7): e0131605","journal-title":"PLoS One"},{"issue":"1","key":"901_CR73","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13058-015-0562-7","volume":"17","author":"KA Snyder","year":"2015","unstructured":"Snyder KA, Hughes MR, Hedberg B, Brandon J, Hernaez DC, Bergqvist P, Cruz F, Po K, Graves ML, Turvey ME, Nielsen JS, Wilkins JA, McColl SR, Babcook JS, Roskelley CD, McNagny KM. Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Res 2015; 17(1): 46","journal-title":"Breast Cancer Res"},{"key":"901_CR74","first-page":"100826","volume":"24","author":"MK Kaneko","year":"2020","unstructured":"Kaneko MK, Ohishi T, Kawada M, Kato Y. A cancer-specific anti-podocalyxin monoclonal antibody (60\u2212mG2a\u2212f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. Biochem Biophys Rep 2020; 24: 100826","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"901_CR75","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/mab.2018.0002","volume":"37","author":"S Yamada","year":"2018","unstructured":"Yamada S, Itai S, Kaneko MK, Kato Y. Anti-podocalyxin monoclonal antibody 47\u2212mG2a detects lung cancers by immunohistochemistry. Monoclon Antib Immunodiagn Immunother 2018; 37(2): 91\u201394","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"issue":"3","key":"901_CR76","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0002-9440(10)62311-5","volume":"166","author":"V Schacht","year":"2005","unstructured":"Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005; 166(3): 913\u2013921","journal-title":"Am J Pathol"},{"issue":"3","key":"901_CR77","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","volume":"4","author":"S Shiina","year":"2016","unstructured":"Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, Natsume A. CAR T cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains. Cancer Immunol Res 2016; 4(3): 259\u2013268","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"901_CR78","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00401-006-0063-y","volume":"111","author":"K Mishima","year":"2006","unstructured":"Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111(5): 483\u2013488","journal-title":"Acta Neuropathol"},{"issue":"9","key":"901_CR79","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/cas.12985","volume":"107","author":"S Abe","year":"2016","unstructured":"Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. Cancer Sci 2016; 107(9): 1198\u20131205","journal-title":"Cancer Sci"},{"issue":"23","key":"901_CR80","doi-asserted-by":"publisher","first-page":"e135306","DOI":"10.1172\/jci.insight.135306","volume":"4","author":"Y He","year":"2019","unstructured":"He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight 2019; 4(23): e135306","journal-title":"JCI Insight"},{"key":"901_CR81","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.1038\/srep05924","volume":"4","author":"Y Kato","year":"2014","unstructured":"Kato Y, Kaneko MK. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep 2014; 4: 5924","journal-title":"Sci Rep"},{"issue":"6","key":"901_CR82","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20(6): 332\u2013342","journal-title":"Trends Mol Med"},{"issue":"2","key":"901_CR83","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/cam4.2733","volume":"9","author":"Z Mei","year":"2020","unstructured":"Mei Z, Zhang K, Lam AK, Huang J, Qiu F, Qiao B, Zhang Y. MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma. Cancer Med 2020; 9(2): 640\u2013652","journal-title":"Cancer Med"},{"key":"901_CR84","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3389\/fimmu.2019.01149","volume":"10","author":"R Zhou","year":"2019","unstructured":"Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol 2019; 10: 1149","journal-title":"Front Immunol"},{"issue":"3","key":"901_CR85","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1089\/1536859041224334","volume":"23","author":"F Rahbarizadeh","year":"2004","unstructured":"Rahbarizadeh F, Rasaee MJ, Forouzandeh Moghadam M, Allameh AA, Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2004; 23(3): 151\u2013159","journal-title":"Hybrid Hybridomics"},{"issue":"4","key":"901_CR86","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/08820130500265356","volume":"34","author":"F Rahbarizadeh","year":"2005","unstructured":"Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh A, Sarrami R, Nasiry H, Sadeghizadeh M. The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin. Immunol Invest 2005; 34(4): 431\u2013452","journal-title":"Immunol Invest"},{"issue":"7","key":"901_CR87","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, Maher J. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008; 180(7): 4901\u20134909","journal-title":"J Immunol"},{"issue":"4","key":"901_CR88","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","volume":"59","author":"F You","year":"2016","unstructured":"You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, Gong Z, Zong Y, Huang L, Lu M, Tang J, Li Y, Zhai X, Wang X, Ye S, Chen D, Yuan L, Qi L, Yang L. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci 2016; 59(4): 386\u2013397","journal-title":"Sci China Life Sci"},{"key":"901_CR89","doi-asserted-by":"publisher","first-page":"628776","DOI":"10.3389\/fimmu.2020.628776","volume":"11","author":"R Zhou","year":"2020","unstructured":"Zhou R, Yazdanifar M, Roy LD, Whilding LM, Gavrill A, Maher J, Mukherjee P. Corrigendum: CAR T cells targeting the tumor MUC1 glycoprotein reduce triple-negative breast cancer growth. Front Immunol 2020; 11: 628776","journal-title":"Front Immunol"},{"issue":"6","key":"901_CR90","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey Jr","year":"2016","unstructured":"Posey ADJr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, Cogdill AP, Chen TJ, Song D, Scholler J, Kranz DM, Feldman MD, Young R, Keith B, Schreiber H, Clausen H, Johnson LA, June CH. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016; 44(6): 1444\u20131454","journal-title":"Immunity"},{"issue":"5","key":"901_CR91","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.immuni.2016.10.014","volume":"45","author":"J Maher","year":"2016","unstructured":"Maher J, Wilkie S, Davies DM, Arif S, Picco G, Julien S, Foster J, Burchell J, Taylor-Papadimitriou J. Targeting of tumor-associated glycoforms of MUC1 with CAR T cells. Immunity 2016; 45(5): 945\u2013946","journal-title":"Immunity"},{"issue":"2","key":"901_CR92","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/bjc.1985.27","volume":"51","author":"N Berry","year":"1985","unstructured":"Berry N, Jones DB, Smallwood J, Taylor I, Kirkham N, Taylor-Papadimitriou J. The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer. Br J Cancer 1985; 51(2): 179\u2013186","journal-title":"Br J Cancer"},{"issue":"S3","key":"901_CR93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ijc.2910410818","volume":"41","author":"A Athanassiou","year":"1988","unstructured":"Athanassiou A, Pectasides D, Pateniotis K, Tzimis L, Natsis P, Lafi A, Arapantoni P, Koutsiouba P, Taylor-Papadimitriou J, Epenetos A. Immunoscintigraphy with 131I-labelled HMFG2 and HMFG2 F(ab\u2032)2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int J Cancer 1988; 41(S3): 89\u201395","journal-title":"Int J Cancer"},{"issue":"6","key":"901_CR94","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ijc.2910540604","volume":"54","author":"A Bamias","year":"1993","unstructured":"Bamias A, Bowles MJ, Krausz T, Williams G, Epenetos AA. Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas. Int J Cancer 1993; 54(6): 899\u2013903","journal-title":"Int J Cancer"},{"issue":"13Supplement","key":"901_CR95","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1158\/1538-7445.AM2019-2052","volume":"79","author":"M Bose","year":"2019","unstructured":"Bose M, Mukherjee P. Abstract 2052: A novel antibody blocks anti-apoptotic activity of MUC1 in pancreatic cancer cell lines. Cancer Res 2019; 79(13 Supplement): 2052","journal-title":"Cancer Res"},{"issue":"7","key":"901_CR96","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/jso.23316","volume":"107","author":"JM Curry","year":"2013","unstructured":"Curry JM, Thompson KJ, Rao SG, Besmer DM, Murphy AM, Grdzelishvili VZ, Ahrens WA, McKillop IH, Sindram D, Iannitti DA, Martinie JB, Mukherjee P. The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J Surg Oncol 2013; 107(7): 713\u2013722","journal-title":"J Surg Oncol"},{"issue":"2","key":"901_CR97","doi-asserted-by":"publisher","first-page":"e0193260","DOI":"10.1371\/journal.pone.0193260","volume":"13","author":"ST Wu","year":"2018","unstructured":"Wu ST, Williams CD, Grover PA, Moore LJ, Mukherjee P. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004. PLoS One 2018; 13(2): e0193260","journal-title":"PLoS One"},{"issue":"4","key":"901_CR98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.tranon.2016.05.001","volume":"9","author":"LJ Moore","year":"2016","unstructured":"Moore LJ, Roy LD, Zhou R, Grover P, Wu ST, Curry JM, Dillon LM, Puri PM, Yazdanifar M, Puri R, Mukherjee P, Dr\u00e9au D. Antibody-guided in vivo imaging for early detection of mammary gland tumors. Transl Oncol 2016; 9(4): 295\u2013305","journal-title":"Transl Oncol"},{"issue":"3\u20134","key":"901_CR99","doi-asserted-by":"publisher","first-page":"536","DOI":"10.18632\/genesandcancer.134","volume":"8","author":"LD Roy","year":"2017","unstructured":"Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue. Genes Cancer 2017; 8(3\u20134): 536\u2013549","journal-title":"Genes Cancer"},{"issue":"3","key":"901_CR100","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","volume":"30","author":"K Lavrsen","year":"2013","unstructured":"Lavrsen K, Madsen CB, Rasch MG, Woetmann A, \u00d8dum N, Mandel U, Clausen H, Pedersen AE, Wandall HH. Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J 2013; 30(3): 227\u2013236","journal-title":"Glycoconj J"},{"issue":"4","key":"901_CR101","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/gast.1997.v113.pm9322511","volume":"113","author":"A Hombach","year":"1997","unstructured":"Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Kruis W, Pohl C, Abken H. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997; 113(4): 1163\u20131170","journal-title":"Gastroenterology"},{"issue":"6","key":"901_CR102","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/0016-5085(95)90763-7","volume":"109","author":"Y Qi","year":"1995","unstructured":"Qi Y, Moyana T, Bresalier R, Xiang J. Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice. Gastroenterology 1995; 109(6): 1950\u20131957","journal-title":"Gastroenterology"},{"issue":"2","key":"901_CR103","first-page":"113","volume":"19","author":"KS Metcalf","year":"1998","unstructured":"Metcalf KS, Selby PJ, Trejdosiewicz LK, Southgate J. Culture of ascitic ovarian cancer cells as a clinically-relevant ex vivo model for the assessment of biological therapies. Eur J Gynaecol Oncol 1998; 19(2): 113\u2013119","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"901_CR104","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00404-015-3675-4","volume":"292","author":"E Myriokefalitaki","year":"2015","unstructured":"Myriokefalitaki E, Vorgias G, Vlahos G, Rodolakis A. Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer. Arch Gynecol Obstet 2015; 292(3): 647\u2013654","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"901_CR105","first-page":"99","volume":"2","author":"A Hombach","year":"1998","unstructured":"Hombach A, Sircar R, Heuser C, Tillmann T, Diehl V, Kruis W, Pohl C, Abken H. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Int J Mol Med 1998; 2(1): 99\u2013103","journal-title":"Int J Mol Med"},{"issue":"1","key":"901_CR106","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","volume":"5","author":"KM Hege","year":"2017","unstructured":"Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer 2017; 5(1): 22","journal-title":"J Immunother Cancer"},{"key":"901_CR107","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","volume":"9","author":"JP Murad","year":"2018","unstructured":"Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol 2018; 9: 2268","journal-title":"Front Immunol"},{"issue":"1","key":"901_CR108","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1023\/A:1006939432665","volume":"15","author":"CA Reis","year":"1998","unstructured":"Reis CA, S\u00f8rensen T, Mandel U, David L, Mirgorodskaya E, Roepstorff P, Kihlberg J, Hansen JE, Clausen H. Development and characterization of an antibody directed to an \u03b1-N-acetyl-D-galactosamine glycosylated MUC2 peptide. Glycoconj J 1998; 15(1): 51\u201362","journal-title":"Glycoconj J"},{"issue":"8","key":"901_CR109","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.25778","volume":"128","author":"JW Pedersen","year":"2011","unstructured":"Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, Poulsen SS, Pedersen AE, Rasmussen S, Jess P, Clausen H, Wandall HH. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011; 128(8): 1860\u20131871","journal-title":"Int J Cancer"},{"issue":"2","key":"901_CR110","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1399-0039.1994.tb02362.x","volume":"44","author":"P Tassone","year":"1994","unstructured":"Tassone P, Bond H, Bonelli P, Tuccillo F, Valerio G, Petrella A, Lamberti A, Cecco L, Turco MC, Cerra M, Montagnani S, Morrone G, Venuta S. UN1, a murine monoclonal antibody recognizing a novel human thymic antigen. Tissue Antigens 1994; 44(2): 73\u201382","journal-title":"Tissue Antigens"},{"issue":"5","key":"901_CR111","doi-asserted-by":"publisher","first-page":"M111.007898","DOI":"10.1074\/mcp.M111.007898","volume":"10","author":"A de Laurentiis","year":"2011","unstructured":"de Laurentiis A, Gaspari M, Palmieri C, Falcone C, Iaccino E, Fiume G, Massa O, Masullo M, Tuccillo FM, Roveda L, Prati U, Fierro O, Cozzolino I, Troncone G, Tassone P, Scala G, Quinto I. Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein. Mol Cell Proteomics 2011; 10(5): M111.007898","journal-title":"Mol Cell Proteomics"},{"issue":"19","key":"901_CR112","doi-asserted-by":"publisher","first-page":"6517","DOI":"10.1073\/pnas.82.19.6517","volume":"82","author":"H Matsuura","year":"1985","unstructured":"Matsuura H, Hakomori S. The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma. Proc Natl Acad Sci USA 1985; 82(19): 6517\u20136521","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"901_CR113","doi-asserted-by":"publisher","first-page":"e135306","DOI":"10.1172\/jci.insight.135306","volume":"4","author":"Y He","year":"2019","unstructured":"He Y, Schreiber K, Wolf SP, Wen F, Steentoft C, Zerweck J, Steiner M, Sharma P, Shepard HM, Posey A, June CH, Mandel U, Clausen H, Leisegang M, Meredith SC, Kranz DM, Schreiber H. Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight 2019; 4(23): e135306","journal-title":"JCI Insight"},{"issue":"5797","key":"901_CR114","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1126\/science.1129200","volume":"314","author":"A Schietinger","year":"2006","unstructured":"Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC, Schreiber H. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006; 314(5797): 304\u2013308","journal-title":"Science"},{"issue":"20","key":"901_CR115","first-page":"5476","volume":"47","author":"J Burchell","year":"1987","unstructured":"Burchell J, Gendler S, Taylor-Papadimitriou J, Girling A, Lewis A, Millis R, Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47(20): 5476\u20135482","journal-title":"Cancer Res"},{"issue":"11","key":"901_CR116","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00262-006-0135-9","volume":"55","author":"A Danielczyk","year":"2006","unstructured":"Danielczyk A, Stahn R, Faulstich D, L\u00f6ffler A, M\u00e4rten A, Karsten U, Goletz S. PankoMab: a potent new generation antitumour MUC1 antibody. Cancer Immunol Immunother 2006; 55(11): 1337\u20131347","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"901_CR117","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/glycob\/cwl061","volume":"17","author":"MA Tarp","year":"2007","unstructured":"Tarp MA, S\u00f8rensen AL, Mandel U, Paulsen H, Burchell J, Taylor-Papadimitriou J, Clausen H. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007; 17(2): 197\u2013209","journal-title":"Glycobiology"},{"issue":"5","key":"901_CR118","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1349-7006.1996.tb00250.x","volume":"87","author":"M Yamamoto","year":"1996","unstructured":"Yamamoto M, Bhavanandan VP, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn J Cancer Res 1996; 87(5): 488\u2013496","journal-title":"Jpn J Cancer Res"},{"issue":"2","key":"901_CR119","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0022-1759(02)00298-3","volume":"270","author":"H Takeuchi","year":"2002","unstructured":"Takeuchi H, Kato K, Denda-Nagai K, Hanisch FG, Clausen H, Irimura T. The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl\u03b12-3galactosyl\u03b21-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. J Immunol Methods 2002; 270(2): 199\u2013209","journal-title":"J Immunol Methods"},{"issue":"4","key":"901_CR120","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000030126","volume":"21","author":"K Ryuko","year":"2000","unstructured":"Ryuko K, Schol DJ, Snijdewint FG, von Mensdorff-Pouilly S, Poort-Keesom RJ, Karuntu-Wanamarta YA, Verstraeten RA, Miyazaki K, Kenemans P, Hilgers J. Characterization of a new MUC1 monoclonal antibody (VU-2-G7) directed to the glycosylated PDTR sequence of MUC1. Tumour Biol 2000; 21(4): 197\u2013210","journal-title":"Tumour Biol"},{"issue":"2","key":"901_CR121","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/glycob\/cwj044","volume":"16","author":"AL S\u00f8rensen","year":"2006","unstructured":"S\u00f8rensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, Sankaranarayanan V, Schwientek T, Graham R, Taylor-Papadimitriou J, Hollingsworth MA, Burchell J, Clausen H. Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006; 16(2): 96\u2013107","journal-title":"Glycobiology"},{"issue":"6","key":"901_CR122","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1159\/000218050","volume":"18","author":"CM Nicolet","year":"1997","unstructured":"Nicolet CM, Siegel DH, Surfus JE, Sondel PM. TAG-72-reactive antibody CC49 recognizes molecules expressed by hematopoietic cell lines. Tumour Biol 1997; 18(6): 356\u2013366","journal-title":"Tumour Biol"},{"issue":"1","key":"901_CR123","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, Han X, Liu Y, Zhang W, Wang C, Zhang Y, Chen M, Yang Q, Wang Y, Han W. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 2020; 13(1): 30","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-021-0901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-021-0901-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-021-0901-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T05:15:46Z","timestamp":1658294146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-021-0901-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["901"],"URL":"https:\/\/doi.org\/10.1007\/s11684-021-0901-2","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"7 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}